La vendita allo scoperto per Accuray dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Accuray. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Accuray (NASDAQ:ARAY) Azioni, Report sulle vendite allo scoperto

Accuray

Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.

Accuray Inc

News

Guidance

ARAY

Accuray Sees FY25 Total Revenue $462M-$472M

Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. The company reported quarterly sales of $101.500 million which beat the analyst consensus estimate of $97.552 million by 4.05 percent. This is a 2.30 percent decrease over sales of $103.892 million the same period last year.

Earnings

Earnings Beats

Accuray Q1 2025 GAAP EPS $(0.04) Beats $(0.05) Estimate, Sales $101.500M Beat $97.552M Estimate

The research builds on previously reported data and shows that at five years, stereotactic body radiation therapy (SBRT) provides comparable rates of cancer control, tolerability and sexual functioning to conventional radiotherapy (CRT), while reducing the overall treatment timeframe from up to 39 days of treatment to just five days. The Accuray <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4280414-1&amp;h=1067734035&amp;u=https%3A%2F%2Fwww.accuray.com%2Fcyberknife%2F&amp;a=CyberKnife">CyberKnife</a>&nbsp;System was used in the SBRT treated arm of the PACE-B study and showed excellent disease control with low rates of toxicity for men with prostate cancer.

Health Care

General

Accuray Announced That Results Of The Pace-B– Prostate Advances In Comparative Evidence – Trial Were Published In The New England Journal Of Medicine

Offerings

Accuray's President And Chief Executive Officer Suzanne Winter To Take Temporary Medical Leave Of Absence; Sandeep Chalke Will Serve As Interim CEO During Winter's Absence

The new system is intended for emerging markets where access to advanced cancer care, including radiotherapy treatments, is typically obtainable only within urban areas and where the availability of linear accelerators per million population is well below the World Health Organization recommended guidelines.

Accuray Secures CE Mark For Accuray Helix, A CT-Guided Helical Radiotherapy System

Accuray Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aray#NASDAQ">ARAY</a>) and Halifax Health announced a breakthrough in cancer treatment at the Charles L. and Miki N. Grant Cancer Center for Hope in Port Orange, FL. The center&#39;s medical team became the first in the United States to treat cancer patients using Accuray&#39;s Radixact System with VitalHold technology. This innovative system is designed to enhance the precision of radiation therapy by improving patient positioning and monitoring throughout the treatment process, offering a new standard of care for a wide range of cancer cases, including breast cancer.
<h3>Significance of Radixact</h3>
Per Accuray, Radixact System, backed by VitalHold and other advanced technologies like ClearRT helical CT imaging and Synchrony real-time adaptive delivery, represents a significant advancement in radiotherapy. VitalHold&#39;s surface-guided radiotherapy (SGRT) ensures accurate patient positioning, improving the reproducibility of treatments and enabling deep inspiration breath hold techniques. This minimizes radiation exposure to critical organs, reducing long-term complications. The system&#39;s tattoo-free positioning further enhances patient experience, making radiation therapy more comfortable and cosmetically appealing.
The anticipated 35% increase in new cancer cases in the United States by 2040 underscores the critical need for advanced resources. Accuray&#39;s Radixact System, equipped with the VitalHold feature, is designed to meet this challenge by providing precise, high-quality radiation therapy from simulation through delivery. Management highlighted the partnership with Halifax Health, where the first U.S. patients have been treated using this innovative system, as a testament to its commitment.
<h3>Industry Prospects</h3>
Per a report in Precedence Research, the global radiation therapy market size is expected to be worth $7.47 billion in 2024. It is anticipated to reach $16.30 billion by 2033 at a CAGR of 8.6%.
The robust growth will be primarily driven by the increasing incidence of cancer, leading to higher demand for radiation therapy. Additionally, advancements in radiation therapy technology, including enhanced ionizing radiation and improved efficiency in targeting cancerous cells, are boosting its effectiveness and utilization in oncology.
Growing awareness about the benefits of advanced radiation therapy, along with initiatives to educate the public, is also accelerating market growth. The integration of innovative features and software systems in radiation therapy will enhance performance, driving increased demand and market value during the forecast period.
In June, Accuray announced that Heidelberg University Hospital in Germany is set to adopt its Radixact System, replacing its older TomoTherapy System.
<h3>Other Industry Players</h3>
Some other companies from the Medical Instruments industry making notable developments in their respective businesses are AngioDynamics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ango#NASDAQ">ANGO</a>), Intuitive Surgical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>) and Masimo Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/masi#NASDAQ">MASI</a>). 
AngioDynamics is a pioneering medical technology company dedicated to advancing vascular health and cancer treatment.
In May, AngioDynamics received European CE Mark approval for its AlphaVac F1885 System, which is designed for the non-surgical removal of thrombi from pulmonary arteries and the treatment of pulmonary embolism.
Intuitive Surgical is a global leader in minimally invasive care and a pioneer of robotic surgery. Known for its da Vinci surgical system and Ion endoluminal system, Intuitive combines cutting-edge technology, advanced learning and supportive services to help healthcare providers deliver optimized patient care.
In June, Intuitive Surgical received FDA clearance for a labeling revision of its da Vinci X and Xi robotic systems specifically for radical prostatectomy. This update reflects real-world evidence showing that long-term survival rates for patients undergoing robotic-assisted radical prostatectomy are comparable to those receiving non-robotic procedures.
Masimo&#39;s a global medical technology company specializing in advanced monitoring technologies, including pulse oximetry, sensors, patient monitors and connectivity solutions. Known for its Masimo SET pulse oximetry, which has been proven to outperform other technologies in over 100 studies, Masimo&#39;s innovations have improved patient outcomes, particularly in neonates and post-surgical care.
This month, the Masimo W1 medical watch received FDA 510(k) clearance for connectivity with the Masimo SafetyNet telemonitoring solution. This integration allows the Masimo W1 watch, which provides continuous oxygen saturation and pulse rate measurements, to seamlessly transmit data to the Masimo SafetyNet app and clinician portal. This enables remote caregivers, including hospital clinicians, to monitor patient data from anywhere.
<a href="https://www.zacks.com/stock/news/2322538/accuray-s-aray-radixact-for-cancer-treatment-debuts-in-us?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2322538">To read this article on Zacks.com click here.</a>

Large Cap

Mid Cap

Penny Stocks

Small Cap

Management

Markets

Trading Ideas

ANGO

ISRG

MASI

Accuray's Radixact for Cancer Treatment Debuts in US

The Russell 2000 is set for its strongest session in a month, bolstered by renewed confidence in the U.S. economy&#8217;s resilience after recession fears rattled <a href="https://www.benzinga.com/markets">markets earlier this month.</a>
The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) was up 2.8% Thursday afternoon, battling for its best one-day session since July 16, when it rallied 3.4%. The small-cap index outperformed the larger-cap indices, highlighting its heightened sensitivity to economic data.
<h3 class="wp-block-heading">Economic Data Fuels Small-Cap Rebound</h3>
The optimism surrounding the Russell 2000 was bolstered by the release of robust economic data on Thursday. Retail sales for July 2024 exceeded expectations, while initial jobless claims for the previous week came in lower than anticipated, countering recession fears.
Retail sales jumped 1% month-over-month in July, marking a sharp rebound from the downwardly revised 0.2% decline in June. This increase far surpassed the expected 0.3% gain and marked the most significant rise since January 2023. The surge was led by a 3.6% increase in sales at motor vehicle and parts dealers, followed by a 1.6% rise in sales at electronics and appliance stores.
On the labor market front, initial jobless claims fell from 234,000 to 227,000 for the week ending Aug. 10, defying market expectations of an increase to 235,000. This marks the second consecutive weekly decline since jobless claims reached a near-one-year high of 250,000 in late July.
Don&#8217;t miss out on this unparalleled opportunity:
<ul>
<li><a href="https://www.benzinga.com/events/small-cap/global-small-cap-conference-2024/" target="_blank" rel="noreferrer noopener">Register now to secure your spot at Benzinga&#8217;s Largest SmallCap Conference ever in Chicago!</a></li>
</ul>
<h3 class="wp-block-heading">Economist Takes</h3>
&#8220;The July retail sales data were consistent with our soft-landing economic outlook,&#8221; said Aditya Bhave, Bank of America economist. 
Bhave highlighted that the retail sales control group, which represents over a quarter of total personal consumption expenditures (PCE) and more than 80% of goods spending, has seen annualized increases of 6.8% and 4.4% over the past three and six months, respectively.
&#8220;With inflation cooling off, retail spending is still clearly running above trend. The decline in jobless claims reported today supports our view that a still-solid labor market is propping up consumer spending,&#8221; Bhave added.
In response to Thursday&#8217;s economic data, traders adjusted their expectations for future Federal Reserve rate cuts. The probability of a 25-basis-point rate cut has now increased to 77%, up from 64% just a day earlier and 45% a week ago.
David Morrison, senior market analyst at Trade Nation, stated, &#8220;It appears that the issues caused by the unwinding of the yen carry-trade, the frothiness of the tech sector, and U.S. recession fears have now dissipated. Investors are in a much better mood than they were 10 days ago, although a period of consolidation may be required to fully digest recent gains.&#8221;
<h3 class="wp-block-heading">Thursday&#8217;s Movers In The Russell 2000</h3>
The top five performers within the Russell 2000 index on Thursday were: 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>% (1-day)</td>
</tr>
<tr>
<td>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>)</td>
<td>40.89</td>
</tr>
<tr>
<td>Accuray Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>)</td>
<td>33.43</td>
</tr>
<tr>
<td>Gambling.com Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAMB#NASDAQ">GAMB</a>)</td>
<td>26.22</td>
</tr>
<tr>
<td>Perpetua Resources Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPTA#NASDAQ">PPTA</a>)</td>
<td>24.24</td>
</tr>
<tr>
<td>Telos Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) </td>
<td>24.15</td>
</tr>
</tbody>
</table>
</figure>
Conversely, the top five losers were:
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>% (1-day)</td>
</tr>
<tr>
<td>Terran Orbital Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLAP#NYSE">LLAP</a>)</td>
<td>-41.26%</td>
</tr>
<tr>
<td>SIGA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>)</td>
<td>-34.15</td>
</tr>
<tr>
<td>Spire Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) </td>
<td>-30.05</td>
</tr>
<tr>
<td>B. Riley Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>)</td>
<td>-26.53</td>
</tr>
<tr>
<td>Titan Machinery Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TITN#NASDAQ">TITN</a>)</td>
<td>-10.16</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Join Us At The Benzinga Small Cap Conference</h3>
Stay ahead of the market trends in U.S. small-cap stocks and get in-depth insights from industry experts. Join us at the Benzinga Small Cap Conference in October. 
Secure your spot today by registering at <a href="https://www.benzinga.com/events/small-cap/global-small-cap-conference-2024">Benzinga Small Cap Conference</a>. Don&#8217;t miss this opportunity to gain valuable knowledge and network with key players in the small-cap space.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/08/40399595/bill-ackman-cuts-chipotle-stake-right-before-stock-drop-did-billionaire-see-what-the-market-coul">Bill Ackman Cuts Chipotle Stake Right Before Stock Drop: Did Billionaire See What The Market Couldn&#8217;t?</a></li>
</ul>
Photo: Shutterstock

Equities

Macro Economic Events

Broad U.S. Equity ETFs

Retail Sales

Econ #s

Economics

ETFs

ASTS

GAMB

LLAP

PPTA

RILY

SIGA

SPIR

TITN

Russell 2000 Set For Strongest Session In A Month As US Economy Defies Recession Fears: Small Cap Movers On Thursday

WIIM

Accuray shares are trading higher after the company reported better-than-expected Q4 sales results.

Shares of Lumentum Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) rose sharply during Thursday's session after the company reported better-than-expected fourth-quarter financial results and issued strong f<a href="https://www.benzinga.com/quote/LITE/earnings">irst-quarter revenue guidance.</a>
The company reported quarterly earnings of 6 cents per share which beat the analyst consensus estimate of 3 cents per share.
Lumentum Holdings shares jumped 16.4% to $52.99 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>SciSparc Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRC#NASDAQ">SPRC</a>) rose 90.1% to $0.6123 in today's pre-market trading after the company announced the courts approval to convene a meeting of shareholders to approve a merger with AutoMax.</li>
<li>VS MEDIA Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSME#NASDAQ">VSME</a>) gained 86.2% to $1.33 in pre-market trading after gaining 4% on Wednesday.</li>
<li>Altamira Therapeutics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTO#NASDAQ">CYTO</a>) gained 52.2% to $1.40 in pre-market trading.</li>
<li>Airship AI Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AISP#NASDAQ">AISP</a>) jumped 20.2% to $3.03 in pre-market trading after reporting a profit for the second quarter.</li>
<li>Accuray Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) gained 20.2% to $1.72 in pre-market trading after the company reported better-than-expected fourth-quarter sales results.</li>
<li>Nxu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXU#NASDAQ">NXU</a>) gained 15.2% to $0.39 in pre-market trading.</li>
<li>Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) gained 15.2% to $379.24 in pre-market trading after Berkshire Hathaway added a stake in the company.</li>
<li>Onconetix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) shares rose 13.7% to $0.1707 in pre-market trading after gaining 13% on Wednesday.</li>
<li>Syntec Optics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTX#NASDAQ">OPTX</a>) gained 13.6% to $1.67 in pre-market trading. Syntec Optics Holdings posted second-quarter results on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Turnstone Biologics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSBX#NASDAQ">TSBX</a>) shares declined 40.5% to $1.30 in pre-market trading after the company reported worse-than-expected second-quarter EPS results.</li>
<li>Titan Machinery Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TITN#NASDAQ">TITN</a>) declined 26.9% to $11.24 in pre-market trading as the company reported weak preliminary financial results for the second quarter.</li>
<li>Jianzhi Education Technology Group Company Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZ#NASDAQ">JZ</a>) shares declined 26.9% to $0.65 in pre-market trading after gaining 12% on Wednesday</li>
<li>Vicinity Motor Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEV#NASDAQ">VEV</a>) fell 20.5% to $0.1450 in today's pre-market trading after dipping 12% on Wednesday.</li>
<li>Spire Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) shares dipped 18.5% to $8.28 in pre-market trading after the company announced it filed a Form 12b-25 for late filing of its Q2 2024 report.</li>
<li>Avalon GloboCare Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALBT#NASDAQ">ALBT</a>) fell 18% to $0.3922 in pre-market trading. Avalon GloboCare shares jumped 82% on Wednesday after the company announced its Laboratory Services MSO, LLC has begun manufacturing the GeeWhiz external male catheter.</li>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) shares fell 16.4% to $0.1403 in pre-market trading after the company announced a reverse stock split and authorized share reduction.</li>
<li>Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares fell 16.1% to $0.3227 in pre-market trading following worse-than-expected first-quarter EPS results.</li>
<li>Digital Ally, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) fell 14.6% to $1.160 Inc pre-market trading. Digital Ally shares jumped 62% on Wednesday after the company was granted a U.S. Patent for tracking and analysis of drivers within a fleet of vehicles.</li>
<li>Precigen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>) shares fell 9% to $1.02 in pre-market trading after posting weak quarterly results</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40368892/jim-cramer-avoid-middle-market-plays-like-golub-capital-buy-mueller-industries-it-is-fan">Jim Cramer: &#8216;Avoid Middle Market Plays&#8217; Like Golub Capital, Buy Mueller Industries — &#8216;It Is Fantastic&#8217;</a></li>
</ul>

Pre-Market Outlook

Movers

AEMD

AISP

ALBT

CYTO

DGLY

FFIE

LITE

ONCO

OPTX

PGEN

SPRC

TSBX

ULTA

VSME

Why Lumentum Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket

Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) reported quarterly earnings of $0.03 per share which met the analyst consensus estimate. The company reported quarterly sales of $134.30 million which beat the analyst consensus estimate of $121.51 million by 10.52 percent. This is a 13.53 percent increase over sales of $118.29 million the same period last year.

Accuray Q4 2024 GAAP EPS $0.03, Inline, Sales $134.30M Beat $121.51M Estimate

Accuray And Halifax Health Announced That The Charles L. And Miki N. Grant Cancer Center For Hope Medical Team Is The First In The U.S. To Treat Cancer Patients Using Accuray's Radixact System With Vitalhold Technology

Long-term Customer Heidelberg University Hospital In Heidelberg, Germany, Has Selected Accuray's Radixact System, Equipped With ClearRT, Synchrony, And VOLO Ultra Optimizer Solutions, It Will Replace The Older Generation Accuray Tomotherapy System

Under the terms of the agreement, TrueNorth Medical Physics will offer services that are complementary and supplementary to those supplied by Accuray, acting as an extension of the hospital team &ndash; on-site, remote or hybrid

Contracts

Accuray Announced An Agreement With TrueNorth Medical Physics To Provide Radiation Oncology Departments With Third-party Support Designed To Enhance Their Department's Capabilities

&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4188888-1&amp;h=1164825535&amp;u=https%3A%2F%2Fwww.accuray.com%2F&amp;a=Accuray+Incorporated" target="_blank">Accuray Incorporated</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) announced today that the registration dossier for the Accuray&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4188888-1&amp;h=470521691&amp;u=https%3A%2F%2Fwww.accuray.com%2Fsoftware%2Fprecision-treatment-planning%2F&amp;a=Precision" target="_blank">Precision</a>&reg;&nbsp;Treatment Planning System (TPS) has been approved by the Chinese National Medical Products Administration (NMPA). The Accuray Precision TPS is now available for use with the CNNC-Accuray joint venture Tomo&reg;&nbsp;C radiation therapy system and in combination, will provide medical care teams with a new option for delivering extremely precise and accurate radiotherapy treatments, ultimately expanding access to care for more cancer patients in&nbsp;China.

Government

Regulations

Accuray's Precision Treatment System Gains Approval in China, Expanding Cancer Care Options

<h3>Gainers</h3>
<ul>
<li>MyMD Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYMD#NASDAQ">MYMD</a>) stock rose 46.0% to $2.89 during Thursday's after-market session. The market value of their outstanding shares is at $6.6 million. </li>
<li>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) stock moved upwards by 31.68% to $1.33. The market value of their outstanding shares is at $339.8 million. </li>
<li>China Pharma Holdings, Inc. Common Stock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) shares moved upwards by 12.83% to $0.33. </li>
<li>BiomX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#AMEX">PHGE</a>) stock rose 6.24% to $0.44. The market value of their outstanding shares is at $31.0 million. </li>
<li>Virios Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRI#NASDAQ">VIRI</a>) stock increased by 6.12% to $0.22. The market value of their outstanding shares is at $6.1 million. </li>
<li>Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) stock increased by 5.73% to $1.66. The company's market cap stands at $164.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) stock fell 7.8% to $179.0 during Thursday's after-market session. The company's market cap stands at $28.9 billion. The company's, Q1 earnings came out today. </li>
<li>Intelligent Bio Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBS#NASDAQ">INBS</a>) shares fell 6.64% to $2.23. The company's market cap stands at $6.9 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock decreased by 6.6% to $0.23. The market value of their outstanding shares is at $5.4 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock decreased by 6.14% to $2.45. The company's market cap stands at $58.4 million. </li>
<li>Cosmos Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COSM#NASDAQ">COSM</a>) stock fell 5.0% to $0.66. The market value of their outstanding shares is at $11.0 million. </li>
<li>Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) stock fell 4.99% to $4.0. The company's market cap stands at $164.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABEO

ADAP

COSM

CPHI

Intelligent Bio Solutions Inc. - Common Stock

INBS

MyMD Pharmaceuticals, Inc. - Common Stock

MYMD

ONMD

PHGE

RSLS

VEEV

VIRI

12 Health Care Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) stock moved upwards by 98.4% to $3.83 during Thursday's regular session. The company's market cap stands at $200.6 million. The company's, Q1 earnings came out yesterday. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock moved upwards by 40.1% to $0.19. The market value of their outstanding shares is at $1.2 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) shares increased by 40.05% to $1.76. The company's market cap stands at $44.2 million. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) shares rose 36.26% to $1.42. The company's market cap stands at $9.3 million. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares moved upwards by 32.35% to $0.3. The company's market cap stands at $85.5 million. </li>
<li>Titan Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTNP#NASDAQ">TTNP</a>) shares moved upwards by 25.37% to $8.4. The market value of their outstanding shares is at $7.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) shares fell 27.6% to $1.57 during Thursday's regular session. The market value of their outstanding shares is at $155.6 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Metagenomi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGX#NASDAQ">MGX</a>) shares fell 17.62% to $5.8. The market value of their outstanding shares is at $217.3 million. </li>
<li>Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) stock fell 11.26% to $3.55. The company's market cap stands at $172.7 million. The company's, Q1 earnings came out today. </li>
<li>Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) stock fell 11.13% to $70.24. The company's market cap stands at $10.2 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock fell 10.97% to $1.34. The company's market cap stands at $46.4 million. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) stock declined by 10.84% to $3.0. The market value of their outstanding shares is at $144.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCAB

BRKR

ELEV

JAGX

NUWE

OCEA

SNSE

SYRA

TTNP

12 Health Care Stocks Moving In Thursday's Intraday Session

Accuray shares are trading lower after the company reported worse-than-expected Q3 financial results and issued FY24 revenue guidance below estimates.

<h3>Gainers</h3>
<ul>
<li>Allarity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>) stock moved upwards by 106.6% to $2.83 during Thursday's pre-market session. The market value of their outstanding shares is at $5.5 million. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares moved upwards by 52.84% to $2.95. The market value of their outstanding shares is at $154.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock rose 35.41% to $1.3. The company's market cap stands at $4.6 million. </li>
<li>Context Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) stock rose 34.55% to $1.83. The company's market cap stands at $29.2 million. </li>
<li>Skye Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) stock increased by 25.09% to $16.0. The company's market cap stands at $449.0 million. </li>
<li>Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) stock increased by 24.52% to $0.98. The market value of their outstanding shares is at $203.9 million. The company's, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock fell 12.5% to $0.1 during Thursday's pre-market session. The market value of their outstanding shares is at $1.2 million. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) stock fell 11.7% to $4.53. The company's market cap stands at $306.8 million. </li>
<li>Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) stock decreased by 11.06% to $1.93. The market value of their outstanding shares is at $191.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Concord Medical Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) shares decreased by 10.92% to $0.68. The market value of their outstanding shares is at $29.5 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock declined by 9.95% to $0.62. The company's market cap stands at $119.8 million. </li>
<li>Pharming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAR#NASDAQ">PHAR</a>) shares decreased by 9.86% to $9.42. The company's market cap stands at $634.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

ALLR

APVO

BFLY

CNTX

CTMX

DBVT

PHAR

SKYE

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Accuray Sees FY24 Revenue $432M-$437M Vs $462.077M Est.

The latest update is out from Accuray ( ($ARAY) ). Suzanne Winter has returned to her role as President and CEO of Accuray Incorporated after a med...

Accuray Welcomes Back CEO Suzanne Winter for Growth

Accuray CEO Suzanne Winter returns from medical leave of absence

Accuray ( ($ARAY) ) just unveiled an update. Accuray Incorporated has announced the appointment of Michael Murphy as Vice President, Corporate Cont...

Accuray Appoints Michael Murphy as VP Corporate Controller

Here are the major earnings after the close today

Reports Q1 revenue $101.5M, consensus $97.55M. We continue to make solid progress in the execution of our strategic growth agenda and performed bet...

Accuray reports Q1 EPS (4c), consensus (5c)

Accuray GAAP EPS of -$0.04 beats by $0.01, revenue of $101.5M beats by $3.95M

Accuray Incorporated (ARAY) Q1 2025 Earnings Call Transcript

Lake Street Keeps Their Buy Rating on Accuray (ARAY)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Petmed Express (PETS – Research Report), Myomo (MYO – Research Re...

Analysts Offer Insights on Healthcare Companies: Petmed Express (PETS), Myomo (MYO) and Accuray (ARAY)

Roth MKM analyst Jason Wittes maintained a Buy rating on Accuray (ARAY – Research Report) today and set a price target of $7.00. The company's shar...

Roth MKM Reaffirms Their Buy Rating on Accuray (ARAY)

ACAD

ACLS

ADTN

AEVA

ALTO

AMPH

AMPY

AMRK

ANSS

APPS

ARQT

ASPN

BBDC

BIRD

DUOL

ENLC

GPMT

HCAT

HRTG

HUBS

IIPR

IONQ

JAZZ

JOBY

KNTK

LAND

LILA

LILAK

LOPE

LUNMF

LYFT

MATV

MEOH

MKSI

MRMD

MTCH

NDLS

NEWT

NMIH

NVGS

PETS

Press Releases

Accuray Reports Fourth Quarter and Fiscal 2024 Financial Results

Accuray Receives CE Mark for a New Helical Radiation Delivery System, Accuray Helix™

Accuray President and Chief Executive Officer Suzanne Winter to Take Temporary Medical Leave of Absence

Gifu Prefectural General Medical Center Achieves Milestone with Treatment of the First Cancer Patients in Japan Using the Accuray Radixact® System and VitalHold™ Solution

Accuray Celebrates Opening of Genolier Innovation Hub in Switzerland, Initiation of CyberKnife® S7™ System Medical Professional Training

Accuray President and Chief Executive Officer Suzanne Winter Returns from Medical Leave of Absence

New England Journal of Medicine Study Reaffirms Five Session Radiation Treatment Provides Comparable Rates of Cancer Control, Tolerability and Sexual Functioning to Conventional Radiotherapy Treatment in Men with Localized Prostate Cancer

Accuray Appoints Michael Murphy as VP, Corporate Controller

Accuray to Report First Quarter Fiscal 2025 Financial Results on November 6, 2024

Comments

Accuray

Vendite allo scoperto

Accuray (NASDAQ:ARAY) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO